Epidermal growth factor receptor testing

Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch. Pathol. Lab. Med. 2007 131 18-43. 

Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118-145. 

Van de Vijver, M. J. 2001. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur. J. Cancer 37 511-517. 

Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours What is the value of current test methods Eur. J. Cancer. 2005 41 1383-92... 

Twenty-seven out of 44 FDA-approved biopharmaceuticals have been tested in a battery of genotoxicity assays. Eighty-five different assays performed yielded negative results. The most commonly performed assays were the Ames test, the chromosomal aberration assay in human lymphocytes, the mouse lymphoma gene mutation assay, and the mammalian in vivo erythrocyte micronucleus test. Examples of the range of biopharmaceutical products tested include, domase alfa (deoxyribonuclease I-DNAse), trastuzumab (mAb to human epidermal growth factor receptor 2), alteplase (tissue plasminogen activator), infliximab (mAb to the human tumor necrosis factor a). 

Yaziji H, Gown AM. Testing for epidermal growth factor receptor in lung cancer have we learned anything from HER-2 testing [comment]. / Clin Oncol. 2004 22(17) 3646-3648. 

Modified from Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer Searching for the ideal method, [comment]. Clin Cancer Res. 2007 1 3 4954-4955. 

---